Correlation between tissue PD-L1, TMB, and blood PD-L1, MSI biomarkers in patients with advanced-stage non-small cell lung cancer (NSCLC).

被引:0
|
作者
Nandimandalam, Sujitha
Sharma, Nitika
机构
[1] East Carolina Univ, Greenville, NC 27858 USA
[2] East Carolina Univ, Vidant Canc Care, Greenville, NC 27858 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
e21564
引用
收藏
页数:1
相关论文
共 50 条
  • [31] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [32] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
  • [33] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [34] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [35] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [36] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [37] The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Zhang, Shuling
    Bai, Xueli
    Shan, Fengping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [38] Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
    Kallergi, Galatea
    Vetsika, Eleni-Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Messaritakis, Ippokratis
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [39] Programmed death-ligand (PD-L1) expression and tissue heterogeneity in advanced non-small cell lung cancer (NSCLC)
    Decatris, Marios
    Hayes, Mark
    Du Rand, Ingrid
    Ryan, Philip
    Phillips, Aled
    El-Batrawy, Sherouk
    Homewood, Renate
    Thomas, Joy
    Bowden, Caitlin
    Taniere, Phillipe
    LUNG CANCER, 2021, 156 : S29 - S30
  • [40] Concordance of PD-L1 expression detection in non-small cell lung cancer (NSCLC) tissue biopsies between OncoTect iO single cell PD-L1 quantification assay and immunohistochemistry (IHC).
    Chargin, Amanda
    Morgan, Rian Janine
    Patterson, Bruce Kendrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35